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Abstract. The selection of precursors (for example chelating agents) and development of a technique of chemical 
modification of the target molecules retaining its ability to bind to specific receptors are very important in the synthesis of 
radiopharmaceuticals. As some important precursors for target radiopharmaceuticals omega-iodo-aliphatic carboxylic 
acids and their esters can be used. We have developed an environmentally safe process for producing omega-iodo-
aliphatic carboxylic acids and their esters of the available, inexpensive and low toxic aliphatic cyclic ketones. We 
proposed a new method for the synthesis of the chelating agents omega-thia- or (bis(2-hydroxyethyl)amino)- aliphatic 
carboxylic acids (chelate 1 and chelate 2), which was caused by the existing disadvantages in the existing methods. Thus, 
based on our method the precursors (chelates) with yield of over 70–90% on the final stage were synthesized, and then 
the high effectiveness in producing target radiopharmaceuticals using different biomolecules was showed. 99mTc-chelates 
complexes were prepared with radiochemical purity >91% and found to be stable at room temperature for six hours. 
INTRODUCTION 
Radiopharmaceuticals are drugs containing a radionuclide, and they are used routinely in nuclear medicine for 
diagnosis or therapy of diseases [1]. Diagnostic radiopharmaceuticals are predominantly metal complexes with an 
organic chelator for metal-essential agents or a chelator-biomolecule conjugate for target-specific 
radiopharmaceuticals. Radiopharmaceuticals can be macromolecules such as monoclonal antibodies, antibody 
fragments, small peptides and hormones. This class is often named target-specific radiopharmaceuticals. Generally, 
a target-specific radiopharmaceutical is based on the receptor binding a radiolabeled receptor ligand in the diseased 
tissue [2–6]. In general, a target-specific radiopharmaceutical can be divided into four parts: targeting biomolecule 
(BM), pharmacokinetic modifying linker, bifunctional coupling or chelating agent (BFC), and radionuclide [7]. 
BFC is needed for radiolabeling biomolecules with a metallic radionuclide (for example, 99mTc and 188/186Re) [8]. 
BFC is covalently attached to the targeting molecule either directly or through a linker, and strongly coordinates to 
the radiometal. The choice of BFC is largely determined by the nature and oxidation state of the radiometal. 
Different radiometals require BFCs with different donor atoms and chelator frameworks. Therefore, it is important 
to understand the coordination chemistry of BFCs with any given radiometal to be labeled [9–13]. 
Nearly 80% of radiopharmaceuticals currently available in clinical nuclear medicine are 99mTc compounds due to 
ideal nuclear properties of 99mTc. The 6 h half-life is long enough to allow a radiopharmacist to carry out 
radiosynthesis and prepare the dose, and for nuclear medicine practitioners to collect clinically useful images. At the 
same time, it is short enough to permit administration of millicurie amounts of 99mTc radiopharmaceutical without 
causing a significant radiation dose to the patient. The monochromatic 140 KeV photons are readily collimated to 
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give images of high spatial resolution. Furthermore, 99mTc is readily available from the 99Mo-99mTc generators at low 
cost [14]. 
An ideal BFC is that which is able to form a stable 99mTc complex in high yield at very low concentration of the 
BFC-BM conjugate. To achieve this goal, the BFC must selectively stabilize an intermediate or lower oxidation 
state of Tc so that the 99mTc complex is not subject to redox reactions. Oxidation state changes are often 
accompanied by transchelation of 99mTc from a 99mTc-BFC-BM complex to the native chelating ligands in biological 
systems. The BFC should form a 99mTc complex which has thermodynamic stability and kinetic inertness with 
respect to dissociation or release of 99mTc. The BFC should form the 99mTc complex with a minimum number of 
isomers since different isomeric forms of the 99mTc-chelate may result in significantly different biological and 
pharmacokinetic characteristics of the 99mTc-BFC-BM complex. Finally, the conjugation group should be easily 
attached to the targeting biomolecule [7]. 
The particularly important tasks in radiochemical synthesis are the selection of a chelating agent and the 
development of a technique for chemical modification of the peptide retaining its ability to bind to specific receptors. 
We proposed a new method for the synthesis of the chelating agents, which was caused by the existing 
disadvantages in the existing synthetic methods. We have developed an environmentally safe process to produce Ȧ-
iodohexanoic acid and its esters of the available, inexpensive and low toxic aliphatic cyclic ketones [13]. Methyl 6-
iodohexanoate was an important precursor for the synthesis of the chelating agents. 
In this work, we describe the processes for the synthesis of the chelating agents 6-thiahexanoic acid (Chelate 1) 
and methyl 6-(bis(2-hydroxyethyl)amino)hexanoate (Chelate 2) and demonstrate their high efficiency in the 
production of a conjugate with 99mTc. 
EXPERIMENT 
Reagents and Instrumentation 
All commercial reagents were ACS reagent grade and were used without further purification. All other reagents 
and solvents were of commercial quality from freshly opened containers. NMR spectra were recorded with a Bruker 
AM400 and a Varian Unity Inova 300 MHz NMR spectrometer at 300 MHz (1H NMR); chemical shifts are reported 
in parts per million (ppm). 
Technetium eluate for research was obtained from technetium generators "99mTc-GT-TOM". 
Radiochemical purity (RCP) and radiochemical yield (RCY) of the produced pharmaceuticals were determined 
by the method of thin layer chromatography (TLC), using plates PTLC silicagel-AF-A-UV (Sorbfil), the mm size 
20×100. The analyzed sample with the volume of 5 μL was applied to the plate with a thin silica layer of PTLC 
silicagel-AF-A-UV (Sorbfil), size 20×100 mm within the start line. The dried plate was placed in two prepared 
chromatographic chambers with acetone (1) and mix C2H5OH : 25%NH4OH : H2O÷2 : 5 : 5 (2) for 10–40 min, 
depending on the used mix. With acetone, the free pertechnetate migrates with the solvent front, whereas colloidal 
99mTc and 99mTc–Chelate both remain at the application point. With mix (2) as the mobile phase, colloidal 99mTc 
remains at the application point, whereas free pertechnetate and 99mTc–Chelate move with the solvent front. 
To the mixture a chelates 100 ȝl of 1 mg/ml of solution (in water), 120 ȝl sodium citrate solution at a 
concentration of 100 mg/ml, 100 ȝl of a solution of SnCl2 · 2H2O at a concentration of 7 mg/ml and 1 ml of a 99mTc 
eluate with activity of 0.5–3.7 GBq were added in a 10 mL bottle without inserting an air needle. The solution is 
ready for use after mixing and incubation for 40 minutes at room temperature. 
Synthesis of Methyl 6-Iodohexanoate 
To a solution of cyclohexanone (0.294 g, 3 mmol) and iodine (0.381 g, 1.5 mmol) in MeOH (10 mL), copper(I) 
chloride (0.03 g, 0.3 mmol) was added, and then hydrogen peroxide solution (6 mmol, 0.638 g, 32% H2O2, 
d 1.125g/mL) in methanol (4 mL) was added dropwise during 2 h at stirring. After that the solution was stirred at 
room temperature for 10 h, and then hydrogen peroxide (3 mmol, 0.319 g) was added again dropwise during 6 h. An 
aqueous solution of Na2SO3 (1 mL) was added to the reaction mixture and the resulting solution was filtered. 
Dichloromethane (15 mL) was added to the filtrate and the organic layer was washed with saturated aqueous 
NaHCO3 (15 mL), water, brine and dried (Na2SO4). The solvents were removed in vacuum to give methyl  
6-iodohexanoate as a colourless oil (yield 0.599 g, 78%); Rf 0.82 (1:5 ethylacetateҟhexane). 1H NMR (300 MHz, 
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CDCl3): į 3.67 (s, 3H, OCH3), 3.18 (t, 2ɇ, 6-H), 2.32 (t, 2ɇ, 2-H), 1.84 (m, 2ɇ, 4-H), 1.62 (m, 2ɇ, 3-H), 1.43 (m, 
2H, 5-H) ppm. 
Synthesis of Methyl 6-Thiahexanoate 
To a solution of methyl 6-iodohexanoate (0.180 g, 0.7 mmol) in MeOH (1 mL) sodium hydrosulfide 
(NaSHǜnH2O) (0.100 g) was added and the reaction mixture was stirred at room temperature for 30 min. Then 1 mL 
of dichloromethane was added, precipitate was removed by filtration. The solvent was evaporated under reduced 
pressure and the residue dried in vacuum to give methyl 6-thiahexanoate as an yellow solid: yield 0.111 g (98%);  
1H NMR (300 MHz, CDCl3): į 3.66 (s, 3H, Oɋɇ3), 2.67 (t, 2H, 6-H), 2.32 (t, 2H, 2-H), 1.58-1.74 (m, 4H, 3-H, 5-H), 
1.39-1.46 (m, 2H, 4-H) ppm. 
Synthesis of 6-Thiahexanoic Acid 
The acid was prepared according to Minisci (1959) from 0.0656 g (0.27 mmol) of 6-iodohexanoic acid, 0.042 g 
(0.27 mmol) of sodium thiosulfate, 1.5 mL of water, and 1 M NaOH (sufficient to attain pH 7) under reflux for 1 h 
at 50qC. The mixture was then acidified to pH 1 with concentrated HCl and boiled for 2 h. After cooling, the 
reaction mixture was washed with dichloromethane (3×5 mL). The aqueous layer was evaporated under reduced 
pressure and the residue dried in vacuum, which on removal provided the acid as the white crystals: 0.036 g 
(0.24 mmol, 90%); TLC: Rf 0.48 (ethyl acetate-hexane, 5:1). 1H NMR (300 MHz, CDCl3): į 2.69 (t, 2H, 6-H), 2.38 
(t, 2H, 2-H), 1.63-1.81 (m, 4H, 3-H, 5-H), 1.43-1.51 (m, 2H, 4-H) ppm. 
Synthesis of Methyl 6-(Bis(2-Hydroxyethyl)Amino)Hexanoate 
To a solution of methyl 6-iodohexanoate (0.2136 g, 0.83 mmol) in isopropanol (2 mL), diethanolamine (0.149 g, 
1 mmol) and triethylamine (0.14 mL, 1 mmol) were added. After stirring at 50qC for 48 h, isopropanol was 
evaporated and 3 mL of water was added. Then the reaction mixture was extracted with portions of dichloromethane 
(3×5 mL), organic extracts were combined and washed with water (5 mL), brine (5 mL), and dried with Na2SO4. 
The solvents were removed in vacuum and the residue was purified by column chromatography (hexane-EtOAc = 
1:1 v/v). Methyl 6-(bis(2-hydroxyethyl)amino)hexanoate was isolated as an yellow oil (69%). 1H NMR (300 MHz, 
CDCl3): į3.72 (s, Ɉɇ, ɋɇ3), 3.63 (t, ɋɇ2), 2.64 (t, ɋɇ2), 2.53 (t, ɋɇ2), 2.32 (ɬ, ɋɇ2), 1.48 (m, ɋɇ2), 1.39 (m, ɋɇ2), 
1.26 (m, ɋɇ2) ppm. 
In Vitro Stability of 99mTc–Chelates 
The stability of the freshly prepared 99mTc–Chelates was assessed by measuring the RCP through TCL at 1, 2, 3, 
4, 5 and 6 h at room temperature (25°C) after preparation. 
RESULTS AND DISCUSSION 
We have developed a new method for the synthesis of effective chelating agents 6-thiahexanoic acid (Chelate 1) 
and methyl 6-(bis(2-hydroxyethyl)amino)hexanoate (Chelate 2). At present, various methods are known to be used 
for synthesis of the chelating agent which is used to obtain radioconjugates. However, the existing methods for 
producing such agents have drawbacks. 
We have developed an optimized general procedure for the preparation of Chelate 1 and Chelate 2. Previously, 
we have reported an environmentally safe way to obtain Ȧ-iodoalconoic acids and their esters starting from readily 
available, low-cost and low-toxic aliphatic cyclic ketones. This method is based on the Bayer-Villiger reaction 
(Baeyer-Villiger oxidation) and the methods proposed by Nikishin et al. [15]. 
Starting from cyclohexanone, we have developed a simple scheme for the synthesis of the chelating agents. The 
scheme of synthesis includes two steps (Fig. 1). In the first step, the intermediate substrates methyl 6-iodohexanoate 
and 6-iodohexanoic acid are prepared by oxidative cleavage of cyclohexanone. 
In the second step, methyl 6-(bis(2-hydroxyethyl)amino)hexanoate is prepared from methyl 6-iodohexanoate via 
diethanolamine. It was found experimentally that in order to increase the yield of the desired product, synthesis must 








































FIGURE 1. The scheme for synthesis of methyl 6-thiahexanoate, 6-thiahexanoic acid and  
methyl 6-(bis(2-hydroxyethyl)amino)hexanoate 
In the second step, 6-thiahexanoic acid is prepared from 6-iodohexanoic acid via sodium thiosulfate. 
Also, methyl 6-thiahexanoate is prepared from methyl 6-iodohexanoate via sodium hydrosulfide. However, the 
use of sodium hydrosulfide is accompanied by the preparation of a by-product—thioether. To suppress this process, 
the reaction was carried out in methyl alcohol for 30 min without heating. The selected conditions allowed us to 
significantly reduce the by-product content (up to 5–7%). The resulting ester looks like a light yellow crystal with a 
characteristic smell of mercaptans. The next aim was to prepare 6-thiahexanoic acid. For this purpose, we used 
methyl 6-thiahexanoate. Hydrolysis was carried out in a mixture of acetonitrile–water under the action of 
hydrochloric acid at room temperature. In this case, the oxidation of the ether was observed with the formation of a 
by-product (disulphide, up to 20%). If you use 6-iodohexanoic acid to produce 6-thiahexanoic acid via sodium 
hydrosulfide, it increases the formation of a by-product—thioether (up to 40–50%). 
Because of this, we proposed to use 6-iodohexanoic acid and sodium thiosulfate to prepare 6-thiahexanoic acid, 
during the interaction of which S-alkylthiosulphates (Bunt salts) are formed. Then S-alkylthiosulphates can be 
hydrolyzed to 6-thiahexanoic acid. In this synthesis we used different reaction conditions (solvents, time, 
temperature and excesses of reagents) and developed the effective procedure. The resulting acid looks like a white 
crystal with a weak odor, turning yellow in the light. 
The results of binding chelates with technetium-99m depending on the amount of relucting agent are showed in 
Table 1. As can be seen from the presented data, the largest radiochemical yield with a low impurity content of 
unreduced and hydrolyzed technetium-99m was observed in case of adding 100 ȝl solution of stannum chloride to 
100 ȝl solution of chelates and 120 ȝl sodium citrate solution, it was more than 91.0%. Radiochemical yield was 
dropping as a large amount of stannum chloride was added due to the increase in formed hydrolyzed technetium-
99m colloid. Thus the optimal conditions were proposed: 100 ȝl solution of chelates in concentration of 1.0 mg/ml 
(in water), 120 ȝl solution of sodium citrate in concentration of 100 mg/ml, 100 ȝl solution of SnCl2 2H2O with 
concentration of 7 mg/ml and 99mTc with activity of 0.5–3.7 GBq. 
The complexes 99mTc–Chelates prepared under optimal radiolabeling conditions were found to be stable at room 
temperature during 6 h after preparation. At 1 h, the RCP reached a maximum of 96.1%. Then, the RCP was found 
to be 91.1%, 91.3%, 91.4%, 91.0% and 90.7% at 2, 3, 4, 5 and 6 h post-labeling, respectively.  
TABLE 1. Radiochemical yield of 99mTc–Chelate 1 and 99mTc–Chelat 2 complexes 
Labeled compound Radiochemical yield, % Percentage of 99mTc–Sn colloid, % 
99mTc–Chelate 1 94.0 2.0–3.0 
99mTc–Chelate 2 92.0 1.0–3.0 
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The labeling efficiency of 99mTc–Chelates were high and its stability duration was long enough to allow further 
biodistribution and imaging studies. 
Thus, based on our method we have developed the synthesis of the chelating agents with yield over 70% in the 
final stage and then have demonstrated high effectiveness in producing a conjugate chelating agents with 99mTc. 
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